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Summary
Background Since 2015, the arthropod-borne viruses (arboviruses) Zika and chikungunya have spread across the 
Americas causing outbreaks, accompanied by increases in immune-mediated and infectious neurological disease. The 
spectrum of neurological manifestations linked to these viruses, and the importance of dual infection, are not known 
fully. We aimed to investigate whether neurological presentations differed according to the infecting arbovirus, and 
whether patients with dual infection had a different disease spectrum or severity.
Methods We report a prospective observational study done during epidemics of Zika and chikungunya viruses in 
Recife, Pernambuco, a dengue-endemic area of Brazil. We recruited adults aged 18 years or older referred to Hospital 
da Restauração, a secondary-level and tertiary-level hospital, with suspected acute neurological disease and a history of 
suspected arboviral infection. We looked for evidence of Zika, chikungunya, or dengue infection by viral RNA or 
specific IgM antibodies in serum or CSF. We grouped patients according to their arbovirus laboratory diagnosis and 
then compared demographic and clinical characteristics.
Findings Between Dec 4, 2014, and Dec 4, 2016, 1410 patients were admitted to the hospital neurology service; 201 (14%) 
had symptoms consistent with arbovirus infection and sufficient samples for diagnostic testing and were included in the 
study. The median age was 48 years (IQR 34–60), and 106 (53%) were women. 148 (74%) of 201 patients had laboratory 
evidence of arboviral infection. 98 (49%) of them had a single viral infection (41 [20%] had Zika, 55 [27%] had chikungunya, 
and two [1%] had dengue infection), whereas 50 (25%) had evidence of dual infection, mostly with Zika and chikungunya 
viruses (46 [23%] patients). Patients positive for arbovirus infection presented with a broad range of CNS and peripheral 
nervous system (PNS) disease. Chikungunya infection was more often associated with CNS disease (26 [47%] of 
55 patients with chikungunya infection vs six [15%] of 41 with Zika infection; p=0·0008), especially myelitis (12 [22%] 
patients). Zika infection was more often associated with PNS disease (26 [63%] of 41 patients with Zika infection vs 
nine [16%] of 55 with chikungunya infection; p≤0·0001), particularly Guillain-Barré syndrome (25 [61%] patients). 
Patients with Guillain-Barré syndrome who had Zika and chikungunya dual infection had more aggressive disease, 
requiring intensive care support and longer hospital stays, than those with mono-infection (median 24 days [IQR 20–30] 
vs 17 days [10–20]; p=0·0028). Eight (17%) of 46 patients with Zika and chikungunya dual infection had a stroke or 
transient ischaemic attack, compared with five (6%) of 96 patients with Zika or chikungunya mono-infection (p=0·047).
Interpretation There is a wide and overlapping spectrum of neurological manifestations caused by Zika or 
chikungunya mono-infection and by dual infections. The possible increased risk of acute cerebrovascular disease in 
patients with dual infection merits further investigation.
Funding Fundação do Amparo a Ciência e Tecnologia de Pernambuco (FACEPE), EU’s Horizon 2020 research and 
innovation programme, National Institute for Health Research.
Copyright © 2020 Elsevier Ltd. All rights reserved.
Introduction 
Over the past 5 years, Brazil has been affected by 
unprece dented outbreaks of arthropod-borne virus (arbo-
virus) infections, including Zika and chikungunya 
viruses, on a background of about 40 years of dengue 
circulation.1–4 All three viruses are transmitted by 
Aedes aegypti mosquitoes and cause febrile illnesses with 
arthralgia and rash; dengue virus can also cause 
haemorrhagic disease and vascular leak, and it is occa-
sionally linked to neurological disease.1 The role of 
chikungunya and Zika viruses in causing neurological 
disease, which can result in disability and death, is being 
recognised increasingly by clinicians, particularly in 
endemic areas.5–7
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An association between Zika virus and Guillain-Barré 
syndrome was first described in French Polynesia in 
2013,8 and subsequently described elsewhere.9,10 Large 
Zika outbreaks affected Brazil from 2015 onwards, when 
other forms of acute neurological and congenital Zika 
disease were first reported.11,12 The role of Zika virus in 
causing CNS disease after the neonatal period is still not 
well defined, with the literature comprising mostly case 
reports and small case series.5,12–14 Chikungunya virus 
infection has been linked to both CNS and peripheral 
nervous system (PNS) disease, though there have been 
few large studies6 describing its importance.
The diagnosis of infection with these arboviruses is 
based on detection of virus genome by PCR testing 
or measurement of specific IgM antibodies by ELISA. 
Because Zika and dengue are both flaviviruses (family 
Flaviviridae), serological cross-reactivity between them 
can complicate antibody-based diagnostics;15 this is 
not an issue with chikungunya virus because it belongs 
to a different genus and family (Alphavirus, family 
Togaviridae). After infection with an arbovirus, life-
long immunity typically develops. For dengue, sequential 
infection by different serotypes can cause more severe 
disease.16 Although laboratory studies suggest that Zika 
virus entry into cells can be enhanced by dengue 
antibodies,17,18 epidemiological data indicate that previous 
exposure to dengue might protect against symptomatic 
Zika infec tion.19 Infection with more than one pathogen 
is thought to contribute to more severe disease in some 
brain infections.20,21 The effect of previous dengue or 
chikun gunya infection on the risk of developing neuro-
logi cal Zika disease is not known, although arbovirus 
co-infection has been reported in some patients with 
neuro logical disease.13,22
To better understand the spectrum of infectious and 
post-infectious immune-mediated neurological disease 
caused by arboviruses, and the effect of dual infection, 
we studied adults with suspected arboviral neuro-
logical disease in Pernambuco, Northeast Brazil, during 
the 2015–16 Zika and chikungunya outbreaks. We 
were especially interested in whether the pattern of dis-
ease differed according to the infecting arbovirus, and 
whether patients with more than one virus infection had 
a different disease spectrum or severity.
Methods 
Study design and patients 
This prospective observational study was done at Hospital 
da Restauração, Recife, a secondary-level and tertiary-level 
hospital that sees an estimated 70% of the patients 
Research in context
Evidence before this study
We searched PubMed for articles investigating the link between 
neurological disease in adults and infection with arboviruses, 
from database inception to Nov 1, 2019, with no language 
restrictions. Search terms included: “Zika”, OR “chikungunya”; 
“meningitis”, “encephalitis”, “meningoencephalitis”, “myelitis”, 
“myelopathy”, “Guillain-Barré syndrome”, “radiculitis”, 
“mononeuropathy”, “cranial neuropathy”, “stroke”, “transient 
ischaemic attack”, “central nervous system”, “peripheral 
nervous system”, and “neurological”. We found 98 case reports 
and case series, four cohort studies, and two case-control 
studies describing neurological complications of chikungunya 
infection. Encephalopathy was the most common presentation 
and studies were mainly done in India, Reunion Island, the 
French West Indies, and Latin America. Zika has been linked to 
Guillain-Barré syndrome in case-control studies in 
French Polynesia, Brazil, Mexico, and Puerto Rico, and to other 
forms of neurological disease in case reports and series, mainly 
from Latin America, but the full range of neurological 
complications and their relative importance has not been 
described. For both chikungunya and Zika, most reports are for 
a single virus infection, although evidence exists that 
arboviruses increasingly co-circulate. More detailed information 
is needed on the neurological features of patients infected with 
different arboviruses and on the effect of dual infection.
Added value of this study
To our knowledge, this study is the largest of its kind to describe 
the neurological features of infection for several arboviruses 
circulating at the same time, including a thorough investigation 
of patients with dual infection. This approach differentiates our 
study from previous ones, which usually describe specific 
disease syndromes linked to Zika, chikungunya, or dengue virus 
alone. Our study shows a high frequency of dual chikungunya 
and Zika virus infections in patients with neurological disease, 
underscoring the need for clinicians to investigate for evidence 
of both pathogens. Although both chikungunya and 
Zika viruses caused a large range of CNS and peripheral nervous 
system (PNS) manifestations, chikungunya was more often 
associated with CNS disease, especially myelitis, whereas Zika 
was more often linked to PNS disease, especially Guillain-Barré 
syndrome.
Implications of all the available evidence
An increase in acute neurological disease might be a sentinel 
for new Zika or chikungunya virus outbreaks, as was seen in 
2015 across the Americas. Epidemiological studies indicate 
that Zika and chikungunya seroprevelance is not so high as to 
preclude such outbreaks in the future. Our study will help 
clinicans to recognise and appropriately investigate patients 
with arbovirus infections, which will allow them to provide 
accurate diagnosis and plan management accordingly. Policy 
makers should consider the burden of arbovirus-associated 
neurological complications when developing public health 
programmes. Future studies should investigate how often 
arbovirus-associated neurological disease occurs in children, 
an understudied population, and further characterise the 
contribution of arbovirus infections to stroke.
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with neurological conditions in the state of Pernambuco, 
Northeast Brazil. We consecutively recruited patients 
aged 18 years or older who presented to neurology 
inpatient services with symp toms of a suspected arboviral-
associ ated neurological disease: history of fever, arth-
ralgia, or rash within the preceding 12 months, followed 
by paralysis, encephalopathy, a seizure, cranial neuro-
pathy, or other focal deficit. We chose a 12-month window 
because we did not want to make presumptions about 
the latency between infection and neurological disease 
onset. However, we also did an analysis for presenta-
tions within 3 months, recognising that most infection-
related neurological dis ease occurs within this time 
window.23,24 Written informed consent was provided by 
patients, or relatives if they did not have capacity. The 
proto col was approved by the Oswaldo Cruz Foundation, 
Instituto Aggeu Magalhães Ethics Committee (CAAE 
#511·06115·8 000 5190).
Procedures 
Patient history, neurological examination findings, and 
results of investigations—including details of serum 
and CSF testing, neuroimaging, nerve con duction studies, 
and electromyography—were noted on case record forms. 
After a review by a senior neurologist (MLBF), patients 
were classified by use of standardised case definitions,25–31 
with levels of diagnostic certainty (appendix 3 pp 1–7), 
as having CNS disease, if they had well recognised 
arboviral-associated syndromes (encephalitis, including 
men ingo encepha litis, rhombo encephalitis, and cerebel-
litis; mye litis; acute disseminated encephalomyelitis 
[ADEM]; or seizures); PNS disease (Guillain-Barré syn-
drome or a variant such as Miller Fisher syndrome, radic-
u lo pathy, or sensory poly neuropathy); or both. Patients 
with optic neuritis or other cranial nerve lesions, in the 
absence of other disease, were classified as having cranial 
neuro pathies. The remainder were classified as having 
other neurological diseases.
All serum and CSF samples were blindly tested for 
Zika, chikungunya, and dengue virus at the Flavivirus 
Reference Laboratory (Oswaldo Cruz Foundation, 
Pernambuco, Brazil) by use of well established protocols 
(appendix 3, p 8). Zika, chikungunya, or dengue infection 
were diagnosed by presence of viral RNA or specific 
IgM antibodies in serum or CSF, as defined previously.13 
Patients with more than one virus detected on PCR 
or IgM antibody testing were classified as having dual 
infection, accepting that infec tions might be contem-
poraneous or sequential. If both viruses were detected at 
the same time by RT-PCR, we classified this as co-
infection. When a patient’s samples were positive for IgG 
but negative for IgM antibodies and virus detection on 
PCR, this was taken to indicate previous exposure to 
the virus.
Samples with IgM antibodies for Zika and dengue virus 
were also assessed for neutralising antibodies against 
these viruses by use of plaque reduction neutralisation 
testing (PRNT) to exclude false positives due to flavivirus 
Figure 1: Study population
Eligible patients presented with neurological disease to the hospital neurology service in Recife between Dec 4, 2014, and Dec 4, 2016. CHIKV=chikungunya virus. 
DENV=dengue virus. PNS=peripheral nervous system. ZIKV=Zika virus.
1410 patients assessed for eligibility
1209 excluded
            1161 did not meet inclusion criteria
                    3 declined participation
                  37 died before recruitment into the study
                    8 had insufficient samples for diagnostic testing 
201 included
64 diagnosed with CNS 
       disease
       49 (77%) positive
              33 mono-infection
                       6 ZIKV
                    26 CHIKV
                       1 DENV
              16 dual infection
                       2 ZIKV and 
                          CHIKV 
                          co-infection
                    11 ZIKV and 
                          CHIKV
                       3 CHIKV and 
                           DENV
        15 (23%) negative
70 diagnosed with 
      PNS disease
      51 (73%) positive
            36 mono-infection
                   26 ZIKV
                      9 CHIKV
                      1 DENV
             15 dual infection
                      6 ZIKV and 
                          CHIKV 
                          co-infection
                      9 ZIKV and 
                          CHIKV
                      0 CHIKV and 
                          DENV
      19 (27%) negative
10 diagnosed with mixed 
      CNS and PNS disease
       7 (70%) positive
           5 mono-infection
               2 ZIKV
               3 CHIKV
               0 DENV
           2 dual infection
               1 ZIKV and CHIKV 
                  co-infection
               1 ZIKV and CHIKV
               0 CHIKV and DENV
       3 (30%) negative
28 diagnosed with isolated 
       cranial nerve disease
       18 (64%) positive
              12 mono-infection
                    3 ZIKV
                    9 CHIKV
                    0 DENV
                6 dual infection
                    1 ZIKV and CHIKV 
                       co-infection
                    5 ZIKV and CHIKV
                    0 CHIKV and 
                        DENV
       10 (36%) negative
29 diagnosed with other 
       neurological disease
       23 (79%) positive
             12 mono-infection
                   4 ZIKV
                   8 CHIKV
                   0 DENV
             11 dual infection
                   3 ZIKV and CHIKV 
                       co-infection
                   7 ZIKV and CHIKV
                   1 CHIKV and 
                      DENV
          6 (21%) negative
See Online for appendix 3
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cross-reactivity. If patients had neutralising antibodies 
against both viruses without a positive PCR test con-
firming infection with one or the other, we deemed this to 
be an indeterminate flavivirus infection and, given the 
epidemiological linkage,4 presumed it to be Zika virus 
infection, as have others previously.9 We also repeated our 
analysis excluding these patients. 
We collected data about admission to intensive care, the 
need for mechanical ventilation, ongoing disability at 
discharge, and death.
Statistical analysis 
Our primary aim was to describe and compare demo-
graphic and clinical features (including neurological 
Figure 2: Epidemiological data
Map of neurological disease case locations in Pernambuco state, Brazil (A), and patient recruitment rate per month over the study period, grouped according to 
arbovirus laboratory diagnosis (B). Mono-infection was defined as laboratory test evidence of infection with a single virus; dual infection was defined as evidence of 
infection with more than one virus on the basis of a positive PCR or IgM test, in whom infection might be concurrent or sequential. Additionally, there were 
two patients with dengue mono-infection in 2015; four patients with chikungunya and dengue dual infection between November, 2015, and April, 2016; and 
53 patients without laboratory evidence of arbovirus infection recruited over the study period. 
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symptoms and diagnosis) of patients across the different 
arboviral diagnostic groups. We used the χ² test for 
comparing categorical variables, or Fisher’s exact test if 
the observations were fewer than five, in a two-tailed 
analysis. For continuous variables, which were not 
normally distributed, we compared medians by use of the 
K Sample equality-of-medians test.32 Logistic regression 
models were used to provide estimates of the odds of 
having certain outcomes adjusted for demographic and 
baseline characteristics, including age, sex, history of 
hypertension, diabetes, and previous dengue infection. 
Missing data were coded as such and were included in 
analyses. We considered a two-sided p value lower than 
0·05 to be significant (appendix 3, p 8). Analyses were 
done using Stata, version 14.1. 
Role of the funding source 
The funders of the study had no role in study design, data 
collection, data analyses, data interpretation, or writing of 
the Article. The corresponding authors had full access to 
all the data, and had final responsibility for the decision 
to submit for publication.
Results 
Between Dec 4, 2014, and Dec 4, 2016, 1410 patients 
were admitted to the neurology service. 249 had sus-
pected arbovirus-associated neurological disease, of whom 
37 (15%) were too unwell to be recruited to the study and 
died shortly after hospital admission, and three (1%) 
declined participation. Of the remaining 209 (84%) 
patients, 201 (81%) had sufficient samples for diagnostic 







p value* ZIKV + CHIKV 
co-infection 
(n=13)
ZIKV + CHIKV 
(n=33)
CHIKV + DENV 
(n=4)
p value† Laboratory 









Age (years) 41 (30–50) 53 (34–68) 38 (35–41) 0·059 47 (28–54) 57 (42–67) 51·5 (42–71) 0·17 48 (34–63) 44 (34–53) 0·23
Sex ·· ·· ·· 0·33 ·· ·· ·· 0·23 ·· ·· 0·052
Men 22 (54%) 24 (44%) 1 (50%) ·· 9 (69%) 18 (55%) 2 (50%) ·· 76 (51%) 19 (36%) ··
Women 19 (46%) 31 (56%) 1 (50%) ·· 4 (31%) 15 (45%) 2 (50%) ·· 72 (49%) 34 (64%) ··
Area of 
residence
·· ·· ·· 0·20 ·· ·· ·· 0·068 ·· ·· 0·058
Recife City 15 (37%) 19 (35%) 0 ·· 2 (15%) 17 (52%) 2 (50%) ·· 55 (37%) 16 (30%) ··
Metropolitan 
region
13 (32%) 10 (18%) 1 (50%) ·· 8 (62%) 9 (27%) 1 (25%) ·· 42 (28%) 24 (45%) ··
Other area of 
Pernambuco
13 (32%) 26 (47%) 1 (50%) ·· 3 (23%) 7 (21%) 1 (25%) ·· 51 (34%) 12 (23%) ··
Systemic features of infection
Fever 21 (51%) 47 (85%) 1 (50%) 0·0003 11 (85%) 31 (94%) 4 (100%) 0·0063 114 (77%) 33 (62%) 0·037
Rash 37 (90%) 43 (78%) 0 0·12 10 (77%) 31 (94%) 2 (50%) 0·36 123 (83%) 43 (81%) 0·75
Pruritus 13 (32%) 18 (33%) 2 (100%) 0·92 5 (38%) 14 (42%) 3 (75%) 0·29 55 (37%) 15 (28%) 0·25
Non-purulent 
conjunctivitis
13 (32%) 15 (27%) 0 0·64 4 (31%) 8 (24%) 3 (75%) 0·70 43 (29%) 16 (30%) 0·88
Myalgia 20 (49%) 37 (67%) 2 (100%) 0·068 7 (54%) 25 (76%) 3 (75%) 0·24 94 (64%) 32 (60%) 0·69
Joint oedema 16 (39%) 36 (65%) 0 0·010 4 (31%) 20 (61%) 1 (25%) 0·82 77 (52%) 18 (34%) 0·024
Arthralgia 25 (61%) 47 (85%) 1 (50%) 0·0061 8 (62%) 28 (85%) 3 (75%) 0·67 112 (76%) 28 (53%) 0·0019
Vomiting 8 (20%) 16 (29%) 0 0·29 6 (46%) 13 (39%) 1 (25%) 0·048 44 (30%) 19 (36%) 0·41
Diarrhoea 3 (7%) 9 (16%) 0 0·19 4 (31%) 5 (15%) 0 (0%) 0·27 21 (14%) 10 (19%) 0·42
Sore throat 5 (12%) 4 (7%) 0 0·64 1 (8%) 3 (9%) 1 (25%) >0·99 14 (9%) 4 (8%) 0·92
Difficulty 
breathing
7 (17%) 4 (7%) 0 0·24 5 (38%) 3 (9%) 0 0·33 19 (13%) 10 (19%) 0·29
Cough 9 (22%) 3 (5%) 0 0·016 2 (15%) 6 (18%) 2 (50%) 0·43 22 (15%) 4 (8%) 0·17
Data are median (IQR) for continuous data and n (%) evaluable for categorical data. Mono-infection was defined as laboratory test evidence of infection with a single virus; dual infection was defined as 
evidence of infection with more than one virus on the basis of a positive PCR or IgM test—infection might be concurrent or sequential; co-infection was defined as contemporaneous detection of RNA of 
more than one virus on PCR testing. Patients with dengue infection were excluded from the mono-infection comparison, because only two were assessed in the study, as well as from the dual-infection 
comparison, because only four patients were assessed in the study. Significant differences remained when we excluded the five patients positive for flavivirus classified as having Zika infection on 
epidemiological grounds. CHIKV=chikungunya virus. DENV=dengue virus. ZIKV=Zika virus. *p values comparing Zika mono-infection versus chikungunya mono-infection cases. †p values comparing Zika or 
chikungunya mono-infection versus Zika and chikungunya co-infection cases. ‡p values comparing cases with laboratory evidence of acute arbovirus infection with those without. §Overall, four (2%) of 
201 patients included in the study reported previous yellow fever vaccination, 56 (28%) hypertension, and 21 (10%) diabetes—these baseline and comorbidity data did not differ between arbovirus 
diagnostic groups.  
Table 1: Demographics and clinical features of the 201 patients in the study population grouped by arboviral laboratory diagnosis
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testing and thus were included in the study (figure 1). 
Patients came from across the Pernambuco state (figure 2). 
The median age was 48 years (IQR 34–60) and 106 (53%) of 
201 patients were women (table 1). Four (2%) of 201 patients 
included in the study reported previous yellow fever 
vaccination, 56 (28%) hypertension, and 21 (10%) diabetes. 
Neuroimaging was done in 150 (75%) patients (118 [59%] 
had MRI, while the other 32 [16%] patients had CT scans 
only), while 24 (12%) had electro physiological peripheral 
nerve studies, and 11 (5%) had EEG.
We collected 363 serum samples and 171 CSF samples 
from the 201 patients: 151 (75%) patients had serum alone 
tested, 49 (24%) had a sufficient sample for both serum and 
CSF arbovirus testing after routine CSF analysis, and 
one (<1%) patient had CSF alone tested. 109 (54%) patients 
had serial serum samples and seven (3%) had more than 
one CSF sample. Overall, 148 (74%) patients tested posi tive 
for arbovirus infection: 98 (49%) with a single virus (mono-
infection), and 50 (25%) with dual infection, including 
13 (6%) with co-infection (table 2; appendix 3, p 9). Of the 
148 arbovirus-positive patients, 41 (28%) had Zika mono-
infection: 17 (11%) were PCR positive (with or without a 
positive IgM) and 24 (16%) were IgM positive alone 
(including 22 [15%] confirmed by PRNT). Two of these 
24 patients were positive for both Zika and dengue IgM and 
could not be differentiated by PRNT, and thus they were 
classified as having Zika virus infection on epidemi ological 
grounds. 55 (37%) patients had chikun gunya mono-
infection: five (3%) were PCR positive (with or without 
IgM) and 50 (34%) IgM positive alone. More patients with 
Zika than with chikungunya infection were included in our 
study in 2015, whereas more patients with chikungunya 
than with Zika infection were included in 2016 (figure 2). 
Only two (1%) patients had dengue mono-infection, both 
were serum IgM positive and confirmed by PRNT (table 2).
Zika and chikungunya dual infection was found in 
46 (31%) of 148 patients: 13 (9%) had co-infection, with 
both viruses detected by PCR (six [4%] in serum and five 
[3%] in CSF; two [1%]  patients were Zika positive in CSF 
and chikungunya positive in serum); 26 (18%) were Zika 
positive with PCR and chikungunya IgM positive (eight 
[5%] were Zika PCR positive in CSF, and 18 [12%] 
in serum); one (<1%) was chikungunya PCR positive 
(in CSF) and Zika IgM positive (CSF and serum); six (4%) 
were positive for Zika and chikungunya IgM antibodies 
in serum alone. Three (2%) of these patients with dual 
infection had evidence of both Zika and dengue IgM and 
a comparable neutralising antibody titre on PRNT, but 
were defined as Zika because of epidemiological link-
age. Four (3%) patients had chikungunya and dengue 
dual infection (on the basis of IgM in serum). Overall, 
179 (89%) of 201 patients had anti-dengue IgG antibodies, 
indicating previous exposure; this did not predispose 
to a specific neurological syndrome, nor did it affect 
clinical outcome.
For the 148 patients positive on arbovirus testing with 
either mono-infection or dual infection, the most 
frequent systemic arbovirus symptoms overall were rash 
(in 123 [83%] patients), fever (114 [77%]), arthralgia 
(112 [76%]), and myalgia (94 [64%]; table 1). Fever, arthralgia, 
and joint oedema were more common in patients with a 
positive arbovirus test than in those with a negative test 
(table 1). Patients with chikungunya mono-infection were 


















PCR alone 2 (5%) ·· ·· 4 (31%) 6 (18%) ··
IgM alone 2 (5%) ·· ·· 0 0 ··
PCR and IgM 1 (2%) ·· ·· 0 0 ··
Serum
PCR alone 4 (10%) ·· ·· 3 (23%) 15 (45%) ··
IgM alone 19 (46%) ·· ·· 0 6 (18%) ··
PCR and IgM 7 (17%) ·· ·· 3 (23%) 1 (3%) ··
CSF and serum
PCR CSF, PCR serum 0 ·· ·· 1 (8%) 0 ··
PCR CSF, IgM serum 0 ·· ·· 0 0 ··
IgM CSF, IgM serum 3 (7%) ·· ·· 0 1 (3%) ··
IgM CSF, PCR serum 0 ·· ·· 0 1 (3%) ··
PCR CSF, PCR serum, IgM CSF 1 (2%) ·· ·· 0 1 (3%) ··
PCR CSF, IgM serum, IgM CSF 1 (2%) ·· ·· 1 (8%) 0 ··
PCR CSF, PCR serum, 
IgM serum
0 ·· ·· 1 (8%) 1 (3%) ··
IgM CSF, PCR serum, 
IgM serum
1 (2%) ·· ·· 0 1 (3%) ··
PCR CSF, PCR serum, IgM CSF, 
IgM serum
0 ·· ·· 0 0 ··
CHIKV
CSF
PCR alone ·· 0 ·· 3 (23%) 0 0
IgM alone ·· 0 ·· 0 0 0
PCR and IgM ·· 0 ·· 0 0 0
Serum
PCR alone ·· 2 (4%) ·· 3 (23%) 0 0
IgM alone ·· 50 (91%) ·· 0 31 (94%) 4 (100%)
PCR and IgM ·· 3 (5%) ·· 5 (38%) 0 0
CSF and serum
PCR CSF, PCR serum ·· 0 ·· 0 0 0
PCR CSF, IgM serum ·· 0 ·· 1 (8%) 1 (3%) 0
IgM CSF, IgM serum ·· 0 ·· 0 1 (3%) 0
IgM CSF, PCR serum ·· 0 ·· 0 0 0
PCR CSF, PCR serum, IgM CSF ·· 0 ·· 0 0 0
PCR CSF, IgM serum, IgM CSF ·· 0 ·· 1 (8%) 0 0
PCR CSF, PCR serum, 
IgM serum
·· 0 ·· 0 0 0
IgM CSF, PCR serum, 
IgM serum
·· 0 ·· 0 0 0
PCR CSF, PCR serum, IgM CSF, 
IgM serum
·· 0 ·· 0 0 0
(Table 2 continues on next page)
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signi ficantly more likely than those with Zika mono-
infection to have fever (47 [85%] of 55 patients with 
chikungunya infection vs 21 [51%] of 41 with Zika infection; 
p=0·0003), joint oedema (36 [65%] vs 16 [39%]; p=0·010), 
or arthralgia (47 [85%] vs 25 [61%]; p=0·0061) and were less 
likely to report cough (three [5%] vs nine [22%]; p=0·016). 
However, rash and conjunc tivitis, often suggested as 
symptoms that can help distinguish Zika from chikun-
gunya infection, did not differ significantly between these 
groups. Compared with patients with mono-infection, 
those with dual infec tion more frequently reported fever 
(68 [71%] of 96 patients with mono-infection vs 42 [91%] of 
46 with dual infection; p=0·0063) and vomiting (24 [25%] 
vs 19 [41%]; p=0·048). These results remained significant 
when we excluded the five patients with positive flavivirus 
tests who were classified as having Zika infection on 
epidemi ological grounds.
The patients who tested positive for Zika, chikungunya, 
or dengue virus—either with mono-infection or dual 
infection—presented with various neurological manifesta-
tions (table 3). The disease syndromes were grouped 
into five disease categories: CNS, PNS, mixed CNS and 
PNS, cranial neuropathy, and other neurological disease 
(table 4). Of the 41 patients with Zika mono-infection, 
six (15%) had CNS disease, 26 (63%) had PNS disease (of 
whom 25 [61%] had Guillain-Barré syndrome), two (5%) 
had mixed CNS and PNS disease, three (7%) had cranial 
neuro pathies, and four (10%) had other neurological 
disease. Of 55 patients with chikun gunya mono-infection, 
26 (47%) had CNS disease, nine (16%) had PNS disease 
(of whom seven [13%] had Guillain-Barré syndrome), 
three (5%) had mixed CNS and PNS disease, nine (16%) 
had cranial neuropathies (including two [4%] with 
abducens nerve paresis), and eight (15%) had other neuro-
logical disease. One (50%) patient with dengue had 
myelitis and the other (50%) had Guillain-Barré syndrome. 
In 46 patients with dual infection with Zika and chikun-
gunya, 13 (28%) had CNS disease, 15 (33%) had PNS dis -
ease, two (4%) had mixed CNS and PNS disease, six (13%) 
had cranial neuropathies, and ten (22%) had other 
neurological disease.
We observed an overall difference in neurological mani-
festa tions depending on the infecting arbovirus. When 
comparing the clinical features of patients with Zika 
mono-infection with those of patients with chikungunya 
mono-infection, patients diagnosed with Zika infection 
presented more often with facial weakness, quadriparesis, 
or hyporeflexia on examination (table 3) and were more 
often diagnosed with PNS disease (26 [63%] of 41 patients 
with Zika infection vs nine [16%] of 55 with chikun-
gunya infection, p<0·0001; odds ratio [OR] 0·11, 95% CI 
0·04–0·29), mainly Guillain-Barré syndrome (table 4). 
Patients with chikungunya mono-infection presented 
more frequently with confusion, hyperreflexia, or sensory 
level on examination (table 3) and were more commonly 
diagnosed with CNS disease (26 [47%] with chikungunya 
infection vs six [15%] with Zika infection, p=0·0008; 
OR 5·23, 95% CI 1·90–14·43; table 4). These results were 
not affected by adjustment for demographic factors or 
comor bidities, and almost all clinical differences persisted 
when we excluded patients who presented with neuro-
logical disease more than 3 months after arbovirus 
infection (appendix 3, pp 10, 12). Patients with dual Zika 
and chikungunya infection presented more often with a 
stroke or transient ischaemic attack than those with either 
infec tion alone (eight [17%] of 46 with dual infection vs five 
[6%] of 96 with mono-infection, p=0·047; OR 3·83, 95% CI 
1·18–12·47). The signifi cance of this result was lost when 
adjusting for age and comorbidities (appendix 3, p 11). We 
did not find a differ ence in the frequency of neurological 
syndromes between patients with a positive arbovirus test 
and those with a negative test (table 4).
We assessed in more detail the neurological syndromes 
seen most frequently in the patients with a positive 
arbovirus test in our study, namely encephalitis (16 [11%] 
patients); myelitis (22 [15%]); ADEM (eight [5%]); and 
Guillain-Barré syndrome (47 [32%]). All 16 patients with 
arboviral encephalitis presented with fever, rash, or both, 
followed by neurological disease; the median interval was 
5 days (IQR 2–5) for patients with Zika mono-infection 
compared with 9 days (6–47) for those with chikun-
gunya infection (p=0·18). Most patients (14 [88%] of 16) 
had altered behaviour or reduced consciousness—only 
patients with cerebellitis or rhombencephalitis did not—
and seven (44%) had seizures; whether patients had 
seizures or not did not differ with viral diagnosis. Of the 
16 patients with arboviral encephalitis, one (6%) with Zika 
infection also had meningism; of those with chikungunya 
infection, three (19%) had limb weakness, two (13%) had 
cerebellar signs, and one (6%) had ophthalmoplegia plus 
bulbar weakness; two (13%) patients with Zika and 
chikungunya dual infection had weakness in all four limbs 
















(Continued from previous page)
DENV
CSF
PCR alone ·· 0 0
IgM alone ·· ·· 0 ·· ·· 0
PCR and IgM ·· ·· 0 ·· ·· 0
Serum
PCR alone ·· ·· 0 ·· ·· 0
IgM alone ·· ·· 2 (100%) ·· ·· 4 (100%)
PCR and IgM ·· ·· 0 ·· ·· 0
Mono-infection was defined as laboratory test evidence of infection with a single virus; dual infection was defined as 
evidence of infection with more than one virus on the basis of a positive PCR or IgM test—infection might be 
concurrent or sequential; co-infection was defined as contemporaneous detection of RNA of more than one virus on 
PCR testing. CHIKV=chikungunya virus. DENV=dengue virus. ZIKV=Zika virus.
Table 2: Summary of diagnostic test results for 148 patients who were positive for an arbovirus
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p value* ZIKV + CHIKV 
co-infection 
(n=13)
ZIKV + CHIKV 
(n=33)
CHIKV + DENV 
(n=4)











Time from systemic 




















Neurological signs and symptoms
Headache 25 (61%) 35 (64%) 1 (50%) 0·79 6 (46%) 23 (70%) 3 (75%) 0·95 93 (63%) 37 (70%) 0·36
Photophobia 4 (10%) 5 (9%) 0 0·91 1 (8%) 2 (6%)  0 0·83 12 (8%) 3 (6%) 0·56
Altered consciousness 7 (17%) 16 (29%) 0 0·17 3 (23%) 12 (36%) 2 (50%) 0·28 40 (27%) 13 (25%) 0·72
Confusion 3 (7%) 16 (29%) 0 0·0081 3 (23%) 9 (27%) 1 (25%) 0·40 32 (22%) 10 (19%) 0·67
Abnormal behaviour 2 (5%) 8 (15%) 0 0·13 3 (23%) 4 (12%) 0 0·41 17 (11%) 6 (11%) 0·97
Seizures 3 (7%) 6 (11%) 0 0·55 1 (8%) 2 (6%) 2 (50%) 0·83 15 (10%) 5 (9%) 0·88
Visual changes 7 (17%) 11 (20%) 0 0·72 2 (15%) 7 (21%) 1 (25%) 0·91 28 (19%) 15 (28%) 0·15
Cranial neuropathy of 
cranial nerve III, IV, or 
VI
3 (7%) 7 (13%) 0 0·61 2 (15%) 1 (3%) 0 0·68 13 (9%) 5 (9%) 0·89
Facial weakness 16 (39%) 9 (16%) 1 (50%) 0·012 4 (31%) 7 (21%) 0 0·79 37 (25%) 13 (25%) 0·95
Bulbar symptoms 9 (22%) 7 (13%) 0 0·23 2 (15%) 10 (30%) 0 0·19 28 (19%) 16 (30%) 0·090
Autonomic 
dysfunction§
7 (17%) 5 (9%) 0 0·24 1 (8%) 1 (3%) 0 0·21 14 (9%) 7 (13%) 0·44
Limb weakness 31 (76%) 38 (69%) 2 (100%) 0·48 9 (69%) 22 (67%) 4 (100%) 0·58 106 (72%) 35 (60%) 0·45
Hemiparesis 1 (2%) 6 (11%) 0 0·11 1 (8%) 5 (15%) 0 0·42 13 (9%) 5 (9%) 0·89
Paraparesis 6 (15%) 15 (27%) 1 (50%) 0·14 2 (15%) 4 (12%) 2 (50%) 0·21 30 (20%) 16 (30%) 0·14
Quadriparesis 24 (61%) 17 (31%) 1 (50%) 0·007 6 (46%) 13 (39%) 2 (50%) 0·87 63 (43%) 14 (26%) 0·038
Abnormal reflexes
Hyporeflexia or absent 
reflexes
25 (61%) 18 (33%) 0 0·0059 7 (54%) 11 (33%) 0 0·52 61 (41%) 17 (32%) 0·24
Hyperreflexia 3 (7%) 13 (24%) 1 (50%) 0·034 2 (15%) 7 (21%) 1 (25%) 0·67 27 (18%) 14 (26%) 0·21
Impaired coordination 8 (20%) 5 (9%) 0 0·14 1 (8%) 2 (6%) 0 0·22 16 (11%) 3 (6%) 0·27
Sensory deficit on 
examination
30 (73%) 33 (60%) 2 (100%) 0·18 8 (62%) 21 (64%) 2 (50%) 0·76 96 (65%) 35 (66%) 0·88
Sensory level 3 (7%) 13 (24%) 1 (50%) 0·034 2 (15%) 9 (27%) 2 (50%) 0·31 29 (20%) 5 (9%) 0·090
Sphincter dysfunction 8 (20%) 18 (33%) 1 (100%) 0·15 3 (23%) 10 (28%) 2 (50%) 0·88 42 (28%) 8 (15%) 0·055
Unable to walk 14 (34%) 16 (29%) 1 (100%) 0·60 5 (38%) 10 (30%) 2 (50%) 0·87 48 (32%) 14 (26%) 0·42
Investigations
White blood cell count 

































CSF cell count 
































Steroids 12 (29%) 31  
(61%; n=51)









Immunoglobulin 24 (58%) 12  
(24%; n=51)









Antivirals 4 (10%) 5  
(9%; n=51)
0 >0·99 0 2  
(7%; n=29)





Anticonvulsants 1 (2%) 1  
(2%; n=51)









(Table 3 continues on next page)
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and one (6%) had dysarthria and dysphonia. Two (13%) 
patients with Zika infection and three (19%) with 
chikungunya infection had CSF pleiocytosis. MRI was 
done in 13 (81%) patients and showed mostly cortical 
lesions. Six (38%) patients were treated with aciclovir for 
possible herpes simplex virus encephalitis, and ten (63%) 
were given steroids (table 3). The median time of hos-
pitalisation for patients with arboviral encephalitis was 
17 days (range 10–24) and ten (63%) of 16 patients had 
motor or cognitive deficits at discharge, with one (6%) 
having ongoing seizures; these results did not differ 
according to viral diagnosis.
The 22 patients with arbovirus-positive myelitis had a 
preceding fever, rash, or both and a median of 12 days 
(IQR 7–28) before the onset of neurological symptoms—
this did not differ according to viral diagnosis. These 
patients typically had paraparesis (14 [64%] patients) or 
quadriparesis (seven [32%]), which was initially flaccid in 
four (18%) patients (all with chikungunya infection), often 
with sensory (21 [95%]) or sphincter involvement (18 [82%]); 
this pattern did not differ according to viral infection. 
Eight (36%) patients with myelitis, all with chikungunya 
mono-infection or dual infection, also had features of 
enceph alopathy. 13 (59%) patients with myelitis had CSF 
pleio cytosis, and six (27%) had elevated protein only. MRI 
was done in 16 (73%) of these patients and confirmed the 
diagnosis of arboviral myelitis in 14 (64%) patients, 
showing thoracic cord inflammation—sometimes with 
cervical or brain stem lesions—but not the more diffuse 
changes seen typically in ADEM. Two (9%) patients with 
myelitis with a normal MRI and six (27%) patients without 
MRI had clinical features of myelopathy, of whom 
four (18%) also had CSF pleiocytosis, indicating inflam-
mation. One (5%) 24-year-old patient with myelitis, 
unilateral visual loss, and Zika and chikungunya dual 
infection had an extensive longitudinal cord lesion plus a 
contrast-enhancing right optic nerve lesion; negative on 
anti-aquaporin-4 antibody testing, he was diagnosed with 
neuromyelitis optica spectrum disorder. 16 (73%) patients 
had corticosteroids and three (14%), with more exten-
sive disease, received immunoglobulin. At discharge, after 
a median 22 days (IQR 17–30) of hospitalisation, all 
22 patients had ongoing disability.
The eight patients with arbovirus-positive ADEM 
presented with various neurological features a median of 
9 days (IQR 5–96) after systemic symptoms. Of these, 
five (63%) patients had reduced consciousness and confu-
sion, three (38%) had behavioural changes, and one (13%) 
had a focal seizure. Seven (88%) patients with ADEM had 
motor deficits, five (63%) also with sensory loss, and 
two (25%) with cranial nerve involvement (one had 
ophthalmoplegia, the other facial and bulbar weakness). 
Five (63%) patients with ADEM had CSF pleiocytosis, and 
in all seven (88%) patients for whom MRI was done, 
it revealed inflammatory white matter changes in the 
brain, cervical, and thoracic spinal cord (figure 3A–C). 
One (13%) patient with encephalopathy and asymmetrical 
quadriparesis did not have MRI and was diagnosed 
clinically as suspected ADEM. All patients with ADEM 
received steroids and three (38%) also received intravenous 
immuno globulin. Patients were discharged after a median 
23 days (IQR 11–29), all with ongoing disability.







p value* ZIKV + CHIKV 
co-infection 
(n=13)
ZIKV + CHIKV 
(n=33)
CHIKV + DENV 
(n=4)











(Continued from previous page)
Inpatient progress and outcome
Intubated 1  
(3%; n=31)
























































Died 0 1 (2%) 0 >0·99 0 0 0 >0·99 1 (1%) 1 (2%) 0·45
Data are median (IQR) for continuous data and n (%) or n (%; N) evaluable for categorical data. Mono-infection was defined as laboratory test evidence of infection with a single virus; dual infection was defined 
as evidence of infection with more than one virus on the basis of a positive PCR or IgM test—infection might be concurrent or sequential; co-infection was defined as contemporaneous detection of RNA of more 
than one virus on PCR testing. Neurological symptom onset was estimated from the patient history (if onset preceded presentation with neurological disease) or was based on the presence of symptoms on 
examination in hospital (if onset of neurological features and infection were concurrent). Patients with dengue infection were excluded from the mono-infection comparison, because only two were assessed in 
the study, as well as from the dual-infection comparison, because only four patients were assessed in the study. Where data were not available for all cases, the denominator is indicated. Significant differences 
remained when we excluded the five patients positive for flavivirus who were classified as having Zika infection on epidemiological grounds. CHIKV=chikungunya virus. DENV=dengue virus. NA=not applicable. 
ZIKV=Zika virus. *p values comparing Zika mono-infection versus chikungunya mono-infection cases. †p values comparing Zika or chikungunya mono-infection versus Zika and chikungunya dual infection cases. 
‡p values comparing cases with laboratory evidence of acute arbovirus infection with those without. §Symptoms of autonomic dysfunction include fluctuations in blood pressure, arrhythmias, vasomotor 
dysfunction, and abnormalities in gastrointestinal motility. ¶Data on neurological disability at discharge was available for 188 (94%) of 199 discharged patients. 
Table 3: Neurological symptoms, treatment, and outcome of study population grouped by arbovirus diagnosis
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47 patients with Guillain-Barré syndrome were positive 
for arbovirus on laboratory testing. Almost all (46 [98%]) 
had a prodrome of fever, rash, or both (one had myalgia 
and pruritus only). These symptoms started a median of 
7 days (IQR 3–17) before neurological symptom onset for 
Zika-associated Guillain-Barré syndrome, which was 
shorter than the median 26 days (15–61) for chikungunya-
associated Guillain-Barré syndrome (p=0·0028), but simi-
lar to the median 9 days (5–20) for patients with Zika 
and chikungunya dual infection. 46 (98%) patients with 
Guillain-Barré syndrome presented with progressive 
paralysis. Facial paralysis was seen in 26 (55%) patients, 
more often bilateral (18 [69%]) than unilateral (8 [31%]). 
16 (34%) of these patients developed bulbar symp-
toms. CSF cytoalbuminological dissoci ation was seen in 
42 (93%) patients. Neurophysiological examination was 







p value* ZIKV + CHIKV 
co-infection 
(n=13)
ZIKV + CHIKV 
(n=33)
CHIKV + DENV 
(n=4)












Total 6 (15%) 26 (47%) 1 (50%) 0·0008 2 (15%) 11 (33%) 3 (75%) 0·54 49 (33%) 15 (28%) 0·52
(Meningo) encephalitis 3 (7%) 9 (16%) 0 0·19 1 (8%) 3 (9%) 0 0·50 16 (11%) 5 (9%) 0·78
Myelitis 1 (2%) 12 (22%) 1 (50%) 0·0060 1 (8%) 5 (15%) 2 (50%) 0·94 22 (15%) 4 (8%) 0·17
ADEM 1 (2%) 5 (9%) 0 0·37 0 2 (6%) 0 0·98 8 (5%) 6 (11%) 0·26
Isolated seizure 1 (2%) 0 0 0·85 0 1 (3%) 1 (25%) >0·99 3 (2%) 0 0·79
PNS
Total 26 (63%) 9 (16%) 1 (50%) <0·0001 6 (46%) 9 (27%) 0 0·65 51 (34%) 19 (36%) 0·86
GBS 25 (61%) 7 (13%) 1 (50%) <0·0001 6 (46%) 8 (24%) 0 0·73 47 (32%) 18 (34%) 0·77
CIDP 0 1 (2%) 0 >0·99 0 0 0 >0·99 1 (1%) 0 >0·99
Radiculitis 1 (2%) 1 (2%) 0 >0·99 0 0 0 0·91 2 (1%) 0 >0·99
Sensory polyneuropathy 0 0 0  ·· 0 1 (3%) 0 0·65 1 (1%) 1 (2%) 0·92
Mixed CNS and PNS disease
Total 2 (5%) 3 (5%) 0 >0·99 1 (8%) 1 (3%) 0 >0·99 7 (5%) 3 (6%) >0·99
Meningoradiculopathy 1 (2%) 0 0 0·85 0 0 0 >0·99 1 (1%) 0 >0·99
Myeloradiculopathy 1 (2%) 1 (2%) 0 >0·99 1 (8%) 1 (3%) 0 0·78 4 (3%) 3 (6%) 0·54
Myelopolyneuropathy 0 1 (2%) 0 >0·99 0 0 0 >0·99 1 (1%) 0 >0·99
Polyneuropathy with meningism 
and encephalopathy
0 1 (2%) 0 >0·99 0 0 0 >0·99 1 (1%) 0 >0·99
Cranial nerves disease
Total 3 (7%) 9 (16%) 0 0·19 1 (8%) 5 (15%) 0 0·93 18 (12%) 10 (19%) 0·23
Optic neuritis 3 (7%) 6 (11%) 0 0·82 1 (8%) 4 (12%) 0 0·99 14 (9%) 9 (17%) 0·14
Abducens nerve paresis§ 0 2 (4%) 0 0·65 0 0 0 0·91 2 (1%) 1 (2%) >0·99
Facial nerve paresis 0 1 (2%) 0 >0·99 0 1 (3%) 0 >0·99 2 (1%) 0 >0·99
Other neurological disease¶
Total 4 (10%) 8 (15%) 0 0·48 3 (23%) 7 (21%) 1 (25%) 0·16 23 (16%) 6 (11%) 0·45
Stroke or transient ischaemic attack 2 (5%) 3 (5%) 0 >0·99 2 (15%) 6 (18%) 0 0·047 13 (9%) 4 (8%) >0·99
Ocular myositis 0 1 (2%) 0 >0·99 1 (8%) 0 0 >0·99 2 (1%) 0 >0·99
Myositis 1 (2%) 2 (4%) 0 >0·99 0 1 (3%) 1 (25%) >0·99 5 (3%) 2 (4%) >0·99
Multiple sclerosis relapse 1 (2%) 1 (2%) 0 >0·99 0 0 0 0·91 2 (1%) 0 >0·99
Amyotrophic lateral sclerosis-like 
syndrome||
0 1 (2%) 0 >0·99 0 ·· 0 >0·99 1 (1%) 0 >0·99
Data are median (IQR) for continuous data and n (%) evaluable for categorical data. Mono-infection was defined as laboratory test evidence of infection with a single virus; dual infection was defined as evidence of 
infection with more than one virus on the basis of a positive PCR or IgM test—infection might be concurrent or sequential; co-infection was defined as contemporaneous detection of RNA of more than one virus 
on PCR testing. Patients with dengue infection were excluded from the mono-infection comparison, because only two were assessed in the study, as well as from the dual-infection comparison, because only four 
patients were assessed in the study. Significant differences remained when we excluded the five patients positive for flavivirus who were classified as having Zika infection on epidemiological grounds. ADEM=acute 
disseminated encephalomyelitis. CHIKV=chikungunya virus. CIDP=chronic inflammatory demyelinating polyneuropathy. DENV=dengue virus. GBS=Guillain Barré syndrome. PNS=peripheral nervous system. 
ZIKV=Zika virus. *p values comparing Zika mono-infection versus chikungunya mono-infection cases. †p values comparing Zika or chikungunya mono-infection versus Zika and chikungunya dual infection cases. 
‡p values comparing cases with laboratory evidence of acute arbovirus infection with those without. §Two (4%) of 55 patients positive for chikungunya virus presented with ophthalmoplegia, diagnosed as 
abducens nerve paresis. ¶Syndromes not widely associated with arbovirus infection were defined as other neurological disease. ||One (2%) of 55 patients positive for chikungunya virus presented 7 months after an 
episode of viral illness with progressive lower limb weakness followed by upper limb weakness, difficulty walking, and dysphagia and was classified as having an amyotrophic lateral sclerosis-like syndrome. 
Table 4: Neurological disease diagnoses of study population grouped by arbovirus diagnosis
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done for 14 (30%) patients, of whom six (43%) had Zika, 
three (21%) chikungunya, and five (36%) Zika and 
chikungunya dual infection. Of these 14 patients, ten (21%) 
had an acute inflammatory demyelinating polyneuropathy, 
two (4%) had acute motor-sensory axonal polyneuropathy, 
and two (4%) had equivocal findings. 16 (34%) patients 
with Guillain-Barré syndrome had spinal cord MRI, with 
none showing inflammation. 41 (87%) patients with 
Guillain-Barré syn drome received immunoglobulin, and 
the remainder received steroids (13%); nine (19%) patients 
were admitted to intensive care, with six (13%) requiring 
invasive ventilation. More patients with Zika and chikun-
gunya dual infection than those with mono-infection were 
admitted to intensive care (five [36%] of 14 vs two [6%] of 
32, p=0·041) and were mechanically ventilated (five [36%] 
of 14 vs one [3%] of 32, p=0·014); their hospital stay was 
also longer (median 24 days [IQR 20–30] for patients with 
dual infection vs 17 days [10–20] for those with mono-
infection; p=0·0028). These differences remained when 
we excluded the three patients with more than 3 months 
from systemic infection to neurological symptom onset 
(appendix 3, p 13). At discharge, 46 (98%) patients with 
Guillain-Barré syndrome had disability, but this did not 
differ according to arboviral diagnosis.
We identified 13 patients admitted with a stroke (n=11) 
or transient ischaemic attack (n=2) who had a preceding 
fever or rash syndrome and were positive for arbovirus on 
laboratory testing: two (15%) patients with Zika infection, 
three (23%) with chikungunya infection, and eight (62%) 
infected with both viruses, including two with co-infection. 
The interval between systemic arbovirus symptoms and 
neurological symptom onset was a median of 119 days 
(IQR 103–134) for patients with Zika infection, 51 days 
(7–124) for those with chikungunya infection, and 88 days 
(14–102) for those with dual infection. 12 (92%) of these 
patients presented with hemiparesis, of whom three (23%) 
had dysarthria, and one (8%) presented with a seizure and 
reduced consciousness only. All patients with stroke or 
transient ischaemic attack underwent imaging: four (31%) 
had MRI, eight (62%) had CT, and one (7%) had both. 
Seven (54%) of these patients had evidence of ischaemic 
changes only and three (23%) had evidence of ischae-
mia with haemorrhagic transformation (figure 3D–I; 
appendix 3, p 14). No distinguishing clinical or radiological 
features were found between patients with mono-infection 
or dual infection who had a stroke or transient ischaemic 
attack. The increased risk of cerebrovascular disease after 
dual infection versus mono-infection remained signifi-
cant, even after excluding patients who presented more 
than 3 months after their febrile syndrome (six [15%] of 
40 patients vs two [2·5%] of 81, p=0·031). We also adjusted 
for age and comorbidities, which are known risk factors 
for stroke. Although age did not differ significantly 
between stroke patients with mono-infection compared to 
dual infection, when adjusting for this and other variables, 
dual infection was no longer a significant risk factor for 
acute cerebrovascular disease (appendix 3, p 11). Median 
age of patients with arbovirus infection and who presented 
acutely with cerebrovascular disease was 65 years 
(IQR 61–78), which was greater than the median age of 
patients with an acute neurological disease other than 
stroke or transient ischaemic attack who tested positive 
for an arbovirus. Additionally, almost all these patients 
Figure 3: Neuroimaging findings
(A) FLAIR MRI of the brain showing bilateral asymmetric hyperintense signal changes in the cortex, most likely 
representing acute demyelination, in a 57-year-old woman with acute disseminated encephalomyelitis. The patient 
presented 14 days after having systemic symptoms of arboviral infection with a reduced level of consciousness, 
bilaterally reduced visual acuity, bilateral lower limb weakness with brisk reflexes, and a T6 sensory level; MRI imaging 
was done on the day of admission. CSF samples were positive for Zika and chikungunya viruses on PCR and 
IgM testing, and serum samples were positive for Zika virus on PCR testing. (B) Coronal FLAIR MRI of the brain of the 
same patient. (C) T2-weighted MRI of the spinal cord of the same patient showing a longitudinally extensive 
intramedullary signal change within the lower thoracic cord extending to the conus (indicated by arrows). 
T2-weighted MRI (D) and DWI MRI (E) of a 78-year-old man positive for chikungunya virus with a stroke. The patient, 
with a history of hypertension, developed left-sided hemiparesis and dysarthria 7 days after onset of systemic 
symptoms of rash, myalgia, arthralgia, and joint oedema. Serum was positive for chikungunya virus IgM antibodies. 
MRI shows features of acute ischaemia, including an area of restricted diffusion involving the left PCA territory (medial 
temporal lobe and the left occipital lobe acute medially, including the lingual gyrus). (F) Follow-up CT at 6 weeks in the 
same patient, showing an established left PCA territory infarct with involution. CT of the head (G), T2-weighted 
MRI (H), and DWI MRI of the brain (I) of a patient positive for Zika and chikungunya virus with a stroke. The patient, a 
64-year-old woman with hypertension, developed a left-sided hemiparesis 12 weeks after onset of systemic viral 
symptoms. Serum was positive for Zika virus on PCR and IgM testing, and chikungunya virus on IgM testing. She 
presented at hospital again 3 months after neurological symptom onset and imaging was done. (G) CT showing an 
area of gyral hyperdensity with surrounding low density change in the left frontal lobe and a mass effect. (H, I) MRI 
imaging showing an area of signal abnormality in the left frontal lobe (middle frontal gyrus) with restricted diffusion 
and areas of susceptibility. These features are suggestive of ischaemia with areas of haemorrhage within it, indicative 
of a subsequent, more recent event after the initial presentation 3 months before. DWI=diffusion-weighted imaging. 
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(12 [92%] of 13) had hypertension, compared with 33 (24%) 
of 135 patients with a positive arbovirus laboratory test 
who did not have cerebrovascular disease (p<0·0001); 
five (38%) had diabetes, and one (8%) had a previous 
stroke. 
Discussion
To our knowledge, our study is the largest of its kind to 
compare Zika-associated and chikungunya-associated 
neurological disease. We have shown that, although the 
viruses cause a similar broad range of CNS and PNS 
manifestations, Guillain-Barré syndrome is predominant 
in patients with Zika infections, whereas CNS disease is 
more common in patients with chikun gunya infections.
The past two decades have seen a remarkable spread 
in the distribution of these emerging arboviruses. 
Chikungunya virus, first identified in Tanzania in 1953, 
caused outbreaks in Africa and southeast Asia in the 
1960s and 1970s. From 2004 onwards, chikungunya virus 
caused large epidemics, spreading to the Pacific Islands in 
2011, and the Americas in 2013.6 Zika virus has spread 
even more rapidly. Isolated initially in Uganda in 1947, the 
virus was considered a benign cause of occasional febrile 
illness.33 However, Zika virus caused large outbreaks in 
Micronesia in 2007, French Polynesia in 2014 (where the 
Guillain-Barré syndrome link was first recognised), and 
Brazil in 2015, where its role in causing microcephaly 
was established.8,11,34 As arboviruses spread, the need to 
understand their severe manifestations and the effect of 
dual infection becomes even more crucial, particularly 
because the areas affected by different viruses overlap 
increasingly.4,13,22
We found that, while both Zika and chikungunya 
viruses can cause Guillain-Barré syndrome, patients 
with Zika infection presented more rapidly after their 
prodromal illness than those with chikungunya infection 
(median 7 vs 26 days). The rapid onset of Guillain-Barré 
syndrome after Zika infection has been suggested as a 
useful distinguishing feature,9,10 reflecting para-infectious 
rather than post-infectious mechanisms,35 but whether 
this time interval is significantly shorter than that for 
other pathogens is unclear.36 High incidence of facial 
involvement has also been suggested as a marker of 
Zika-associated Guillain-Barré syndrome,5 but we found 
that facial involvement was equally common (just higher 
than 50%) in patients with chikungunya-associated 
Guillain-Barré syndrome.
Approximately half of our patients with chikungunya 
infection with CNS presentations had myelitis. Although 
myelitis has been described with chikungunya infection 
before,6 its importance compared with encephalitis has 
not been emphasised previously. In our 2018 systematic 
review, 322 (37%) of 856 patients with chikungunya-
associated neurological disease had encephalopathy, but 
just 19 (2%) had myelopathy.6 We also saw myelitis 
in patients with Zika mono-infection and dual infection in 
our study. Considerable attention has been given to acute 
flaccid myelitis caused by enteroviruses, particularly 
enterovirus D68;37 our study is a pertinent reminder that 
arboviruses should also be considered in such cases in 
endemic areas or in returning travellers. ADEM was 
another important presentation seen in our study, especi-
ally after chikungunya infection; this finding sug gests that 
infection can result in post-infectious immune-mediated 
CNS disease.
We were interested particularly in whether dual 
arbovirus neurological infections were more severe than 
mono-infections, as suggested by preliminary reports13,22 
and seen in other brain infections.20,21 We found that dual 
infections were common, accounting for approximately a 
third of patients with an arbovirus-positive laboratory test, 
and probably reflecting an overlap of two epidemics.4 This 
prevalence of dual infections is higher than that in a 
Brazilian study of non-neurological arboviral disease (with 
9% of patients having dual arbovirus infection),38 but 
lower than that of a small neurological disease study from 
Ecuador (where 75% of patients had arbovirus co-
infection).22 We found that patients with Guillain-Barré 
syndrome and dual infection more often required inten-
sive care support and mechanical ventilation, and spent 
on average nearly 7 days longer in hospital than those with 
Zika or chikungunya mono-infections, which suggests 
that patients with dual infection had more severe disease. 
We found no evidence that patients with previous dengue 
infection had more severe disease than those without, 
although we observed a high rate of previous exposure  to 
dengue across all disease groups.
Intriguingly, presentations with cerebrovascular disease 
were nearly 3 times more common in patients with dual 
infection than in those with mono-infection (17% vs 6%; 
OR 3·83, 95% CI 1·18–12·47), although significance was 
lost when accounting for other much stronger risk factors 
(age, hypertension, and diabetes; appendix 3, p 11). Case 
reports exist of stroke after chikungunya or Zika virus 
infection.14,39 The risk of stroke after infection is known to 
be increased, especially for varicella zoster virus, which 
causes vasculitis, and HIV, which is thought to disrupt the 
vascular endothelium.24,40 Stroke is also being reported 
increasingly in association with COVID-19, caused by 
severe acute respiratory syndrome coronavirus 2.41 A retro-
spective, population-based cohort study of 13 787 patients 
in Taiwan sug gested that stroke risk might also be 
increased after dengue infection.42 Our findings strengthen 
the evidence for a link between cerebrovascular disease 
and arboviral infection, although our patients had other 
risk factors, suggesting that this disease is multifactorial. 
Clearly, a case-control approach is needed to better under-
stand this question.
Our study was limited by the challenges of doing 
research during outbreaks; for example, sample availability 
was limited, and we could not study some patients in 
extremis (eg, those who died before inclusion in the study). 
We only recruited patients admitted under the neurology 
service with preceding symptoms of sys temic arbovirus 
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infection, meaning that we would not have captured 
patients with disease manifestations that were neurological 
alone. Although distinguishing Zika from dengue virus 
can be challenging, we adopted the most robust approaches 
available, including the use of con firmatory neutralisa-
tion antibody testing in cases when doubt remained. 
Nevertheless, for five patients, we were unable to dis-
tinguish serologically between dengue and Zika viruses 
and classified them as Zika on the basis of the epidemiology, 
an approach used previously.9 Excluding these five patients 
did not alter our findings overall.
In summary, we have shown that Zika virus infection 
was associated with various CNS and PNS manifestations 
beyond Guillain-Barré syndrome, whereas for chikun-
gunya virus infection, encephalitis, and myelitis were the 
most important presentations. The overall effect of arbo-
viral outbreaks on neurology services is large: 148 (10%) of 
our 1410 neurology department admissions over 2 years 
were patients with laboratory-confirmed arboviral infec-
tion. We see about 70% of all neurological patients 
in the public health system of Pernambuco (popu-
la tion 9·5 million), so we believe that our findings are 
fairly representative. Clinicians and public health officials 
need to be aware of the wide spectrum of neurological 
diseases linked to arboviruses and appreciate that dual 
infection is common and might affect disease pattern 
and severity.
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